Status:
COMPLETED
ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)
Lead Sponsor:
UCB S.A. - Pharma Sector
Conditions:
Rhinitis, Allergic, Perennial
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Comparison of clinical efficacy and safety of levocetirizine in PER continuous versus on demand, measured by evolution of individual symptom scores during 6 months.
Eligibility Criteria
Inclusion
- Clinical history of Persistent allergic Rhinitis (PER) requiring treatment known at least since 2 years.
- Positive skin prick test (wheal \> 3 mm larger than the diluent control) or Radio Allergo Sorbent Assay (RAST) (\>= 3.5 IU/ml) to House Dust Mite (HDM) and Parietaria (less than 1 year).
- Minimum mean Total 4 Symptom Score (T4SS) of 6 over baseline period.
Exclusion
- Subjects currently treated by specific parietaria pollen immunotherapy
- Subjects suffering from non-allergic asthma
- Chronic use of inhaled steroids and/or long acting β2 agonists; and/or corticosteroids dependent asthma (severe asthma)
- Atopic dermatitis or urticaria requiring antihistamine treatment or the administration of oral or topical corticosteroids
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00160680
Start Date
March 1 2005
End Date
June 1 2006
Last Update
August 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Genova, Italy